Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Menu

Pamelor 10 Mg Caps 30 By MallinckrODT Inc

Image 0 of Pamelor 10 Mg Caps 30 By MallinckrODT Inc Image 1 of Pamelor 10 Mg Caps 30 By MallinckrODT Inc

Pamelor 10 Mg Caps 30 By MallinckrODT Inc

Call for Price

Pamelor 10 Mg Caps 30 By MallinckrODT Inc This Item Requires A Valid Order From A Physician Licensed in USA. Item Number.:RXD3933249/RXB10005609
Size : 30
Selling UoM : EA
NDC: 00406-9910-03
UPC Barcode : 304069910035
Supplier:0050000439 MALLINCKRODT INC.CHEMICAL
Supplier Material : 991003
Generic Code : 046059 NORTRIPTYLINE HCL ORAL CAPSULE 10 MG
Fine Line Class : 850085008510 All Rx Products
Product Category : RX Pharmaceuticals
Product Type : BRX Branded RX

Have a question?

  Call for Price

Product Description.:

Logo and Pamelor 10 mg
capsule , peach white , oblong oblong
M within a squareOpaqueBlack ink

Pamelor? (nortriptyline HCl) is 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo[a,d] cyclohepten-5-ylidene)-N-methyl-, hydrochloride.

10 mg, 25 mg, 50 mg, and 75 mg Capsules

Active Ingredient: nortriptyline hydrochloride USP.

10 mg, 25 mg, and 75 mg Capsules

Inactive Ingredients: D&C Yellow #10, FD&C Yellow #6, gelatin, silicone fluid, starch, and titanium dioxide.

50 mg Capsules

Inactive Ingredients: gelatin, silicone fluid, starch, and titanium dioxide.

Solution

Active Ingredient: nortriptyline hydrochloride USP.

Inactive Ingredients: alcohol, benzoic acid, flavoring, purified water, and sorbitol.

INDICATIONS AND USAGE

Pamelor? (nortriptyline HCl) is indicated for the relief of symptoms of depression. Endogenous depressions are more likely to be alleviated than are other depressive states.

CONTRAINDICATIONS

The use of Pamelor? (nortriptyline HCl) or other tricyclic antidepressants concurrently with a monoamine oxidase (MAO) inhibitor is contraindicated. Hyperpyretic crises, severe convulsions, and fatalities have occurred when similar tricyclic antidepressants were used in such combinations. It is advisable to have discontinued the MAO inhibitor for at least two weeks before treatment with Pamelor? (nortriptyline HCl) is started. Patients hypersensitive to Pamelor? (nortriptyline HCl) should not be given the drug.

Cross-sensitivity between Pamelor? (nortriptyline HCl) and other dibenzazepines is a possibility.

Pamelor? (nortriptyline HCl) is contraindicated during the acute recovery period after myocardial infarction.

WARNINGS

Clinical Worsening and Suicide Risk

Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18-24) with major depressive disorder (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24 there was a reduction with antidepressants compared to placebo in adults aged 65 and older.